Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mevrometostat + enzalutamide versus placebo + enzalutamide in treatment-naive metastatic castration-resistant prostate cancer
2024-511652-40-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Mevrometostat + enzalutamide with Placebo + enzalutamide (2 arms). Primary endpoint: Radiographic progression-free survival. Planned start Feb 2025; status: authorised.
02
Drugs
mevrometostatenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-511652-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511652-40-00.